MESA, AZ / ACCESS Newswire / September 29, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announces a new era of leadership and innovation under CEO Marshall Perkins, whose extraordinary personal journey is now fueling the company's mission to transform healthcare. In early 2025, Perkins faced a near-fatal battle with advanced bone cancer that destroyed multiple vertebrae and left him hospitalized for months. ...

Core Viewpoint - Ping An Healthcare and Technology Company Limited reported strong interim results for the first half of 2025, showcasing significant revenue growth and improved profitability, driven by advancements in its core business and medical AI capabilities [1]. Financial Performance - The Company recorded revenue of RMB2.5 billion, representing a year-on-year increase of 19.5% [2]. - Net profit attributable to shareholders rose to RMB134 million, a year-on-year increase of 136.8% [2]. - Adjusted net profit was RMB165 million, up 83.6% year-on-year [2]. - The gross profit margin increased to 33.6% due to AI enablement and business mix optimization [2]. Core Business Development - Revenue from the integrated finance business ("F-end") and corporate health management business ("B-end") increased by 30.2% year-on-year [3]. - The Company expanded its family doctor services and senior care concierge services, leading to a significant increase in member coverage [3]. - Over 35.0 million users were entitled to family doctor service benefits, while those entitled to home-based senior care benefits increased by 83% year-on-year [3]. Technological Innovation - The Company enhanced its AI-driven healthcare services by leveraging its "data + models + scenario" closed-loop advantage [4]. - The accuracy rate of AI-assisted inquiry and consultation reached approximately 98%, while the accuracy of MDT complex disease treatment was nearly 80% [4]. - AI helped doctors handle up to 4.0 million consultation requests per day and reduced family doctors' average service cost per customer by approximately 52% year-on-year [4]. - Operational efficiency in the middle office improved by approximately 50% year-on-year due to AI-driven process reengineering and optimization [4].

Financial Data and Key Metrics Changes - Doximity reported revenue of $146 million for Q1 FY2026, representing a 15% year-on-year growth and a 4% beat from the high end of guidance [7] - Adjusted EBITDA margin was 55%, amounting to $80 million, which was 11% above the high end of guidance [7] - Free cash flow increased by 52% year-on-year, reaching $60.1 million [22] - Non-GAAP gross margin for Q1 was 91%, down from 92% in the prior year [21] Business Line Data and Key Metrics Changes - Unique active users across all metrics (quarterly, monthly, daily) reached record highs, with double-digit percentage growth year-on-year [9] - The number of unique active prescribers using workflow tools reached 630,000, marking significant engagement [9] - The AI tools experienced over 5x year-on-year growth [9] Market Data and Key Metrics Changes - Doximity's net revenue retention rate was 118% on a trailing twelve-month basis, with the top 20 customers showing a higher rate of 119% [20] - The company ended the quarter with 120 customers contributing at least $500,000 each in subscription-based revenue, a 17% increase from the previous year [21] Company Strategy and Development Direction - Doximity is focusing on AI integration, with the launch of the Doximity AI Scribe and the acquisition of Pathway, aiming to enhance physician productivity [19][23] - The company plans to integrate Scribe into telehealth tools, creating a seamless experience for physicians [13] - Doximity aims to build a comprehensive AI suite that addresses clinical questions and enhances workflow efficiency [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's strength despite ongoing policy uncertainty, noting no slowdown in customer budgets [27] - The outlook for FY2026 includes revenue guidance of $628 million to $636 million, reflecting an 11% growth at the midpoint [25] - Management highlighted the importance of AI investments for long-term growth and productivity improvements [56] Other Important Information - The Pathway acquisition was completed for $26 million in cash and up to $37 million in equity grants, with no expected revenue contribution this year [24] - The company repurchased $122.3 million worth of shares during the first quarter [23] Q&A Session Summary Question: How can you frame the opportunity for investors regarding Scribe, Pathways, and Doximity GPT? - Management sees these AI tools as a potential third act, enhancing physician engagement and addressing clinical questions in real-time [31] Question: Can you provide insights on customer budgets and the second half guidance? - Management noted strong Q1 performance but cautioned against extrapolating this into the second half due to policy uncertainties [36] Question: What are the qualitative differences in upsell cycles this year? - Management indicated broad-based strength across all customer segments, with significant growth in SMB customers [40] Question: How do you view the drivers of continued provider use of products? - Management highlighted the stickiness of workflow tools and the importance of AI in enhancing user engagement [48] Question: Will the new AI offerings become standalone revenue generators? - Management anticipates that AI products like Scribe could evolve into enterprise revenue streams similar to the Doximity Dialer [59] Question: What is the current state of the Provider Solutions business? - Management reported strong traction in the health system business, particularly in enterprise offerings [99] Question: How is the news feed performing and what developments are there? - Management noted record high engagement in the news feed, with video content becoming increasingly important [109]